Tachykinin-induced contraction of the guinea-pig isolated oesophageal mucosa is mediated by NK(2) receptors

Br J Pharmacol. 2000 Dec;131(7):1461-7. doi: 10.1038/sj.bjp.0703708.

Abstract

1. The tachykinin receptor present in the guinea-pig oesophageal mucosa that mediates contractile responses of the muscularis mucosae has been characterized, using functional in vitro experiments. 2. The NK(1) receptor-selective agonist, [Sar(9)(O(2))Met(11)]SP and the NK(3) receptor-selective agonists, [MePhe(7)]-NKB and senktide, produced no response at submicromolar concentrations. The NK(2) receptor-selective agonists, [Nle(10)]-NKA(4 - 10), and GR 64,349 produced concentration-dependent contractile effects with pD(2) values of 8.20+/-0.16 and 8.30+/-0.15, respectively. 3. The concentration-response curve to the non-selective agonist, NKA (pD(2)=8.13+/-0.04) was shifted significantly rightwards only by the NK(2) receptor-selective antagonist, GR 159,897 and was unaffected by the NK(1) receptor-selective antagonist, SR 140,333 and the NK(3) receptor-selective antagonist, SB 222,200. 4. The NK(2) receptor-selective antagonist, GR 159,897, exhibited an apparent competitive antagonism against the NK(2) receptor-selective agonist, GR 64,349 (apparent pK(B) value=9.29+/-0.16) and against the non-selective agonist, NKA (apparent pK(B) value=8.71+/-0.19). 5. The NK(2) receptor-selective antagonist, SR 48,968 exhibited a non-competitive antagonism against the NK(2) receptor-selective agonist, [Nle(10)]-NKA(4 - 10). The pK(B) value was 10.84+/-0.19.6. It is concluded that the guinea-pig isolated oesophageal mucosa is a useful preparation for studying the effects of NK(2) receptor-selective agonists and antagonists as the contractile responses to various tachykinins are mediated solely by NK(2) receptors.

MeSH terms

  • Animals
  • Benzamides / pharmacology
  • Captopril / pharmacology
  • Dose-Response Relationship, Drug
  • Esophagus / drug effects*
  • Esophagus / physiology
  • Guinea Pigs
  • In Vitro Techniques
  • Mucous Membrane / drug effects*
  • Mucous Membrane / physiology
  • Muscle Contraction / drug effects*
  • Neurokinin A / analogs & derivatives
  • Neurokinin A / pharmacology
  • Neurokinin B / analogs & derivatives*
  • Neurokinin B / pharmacology
  • Neurokinin-1 Receptor Antagonists
  • Peptide Fragments / pharmacology
  • Piperidines / pharmacology
  • Protease Inhibitors / pharmacology
  • Quinolines / pharmacology
  • Quinuclidines / pharmacology
  • Receptors, Neurokinin-1 / agonists
  • Receptors, Neurokinin-2 / agonists
  • Receptors, Neurokinin-2 / antagonists & inhibitors
  • Receptors, Neurokinin-2 / physiology*
  • Receptors, Neurokinin-3 / agonists
  • Receptors, Neurokinin-3 / antagonists & inhibitors
  • Substance P / analogs & derivatives*
  • Substance P / pharmacology
  • Tachykinins / pharmacology*
  • Thiorphan / pharmacology

Substances

  • Benzamides
  • Neurokinin-1 Receptor Antagonists
  • Peptide Fragments
  • Piperidines
  • Protease Inhibitors
  • Quinolines
  • Quinuclidines
  • Receptors, Neurokinin-1
  • Receptors, Neurokinin-2
  • Receptors, Neurokinin-3
  • SB 222200
  • Tachykinins
  • neurokinin B, MePhe(7)-
  • senktide
  • neurokinin A (4-10), Nle(10)-
  • substance P, Sar(9)-Met(O2)(11)-
  • neurokinin A (3-10), lysyl(3)-glycyl(8)-R-lactam-leucine(9)-
  • SR 140333
  • Substance P
  • SR 48968
  • Neurokinin A
  • Neurokinin B
  • Captopril
  • Thiorphan